Clinician and patient education is critical for safe administration of checkpoint immunotherapies and screening to identify patients who are not suitable candidates for checkpoint inhibitor therapy.
Clinician and patient education is critical for safe administration of checkpoint immunotherapies and screening to identify patients who are not suitable candidates for checkpoint inhibitor therapy.
Dermatofibrosarcoma protuberans (DFSP) is an uncommon soft tissue tumor characterized by a relatively high risk of local recurrence and low risk of metastasis. The NCCN Guidelines for DFSP provide multidisciplinary recommendations on the management of patients with this rare disease.
This information was originally presented on March 13, 2014, at the NCCN 19th Annual Conference: Advancing the Standard of Cancer Care™ held in Hollywood, Florida.
Many unanswered questions remain about what constitutes appropriate guidelines for treatment of Merkel cell carcinoma (MCC). In this review, we address current uncertainty surrounding optimal management of Merkel cell carcinoma.
This archived webinar series is designed to provide an in-depth analysis of the evidence and clinical decision-making that led to the development of the NCCN Guidelines® for Melanoma and Non-Melanoma Skin Cancers.
This archived webinar series is designed to provide an in-depth analysis of the evidence and clinical decision-making that led to the development of the NCCN Guidelines® for Melanoma and Non-Melanoma Skin Cancers.
This webinar series is designed to provide an in-depth analysis of the evidence and clinical decision-making that led to the development of the NCCN Guidelines® for Melanoma and Non-Melanoma Skin Cancers.
This webinar series is designed to provide an in-depth analysis of the evidence and clinical decision-making that led to the development of the NCCN Guidelines® for Melanoma and Non-Melanoma Skin Cancers.
This congress is a full-day educational program designed to provide an in-depth analysis of the evidence and clinical decision-making that led to the development of the NCCN Guidelines® for Melanoma and Non-Melanoma Skin Cancers.